{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monotherapy+ezetimibe",
    "query": {
      "intervention": "Monotherapy ezetimibe"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T20:01:33.319Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06005597",
      "title": "Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "Hypercholesterolemia",
        "Familial Hypercholesterolemia",
        "ASCVD",
        "High Cholesterol"
      ],
      "interventions": [
        {
          "name": "Combination Therapy",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Monotherapy obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Monotherapy ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Combination Therapy placebo",
          "type": "OTHER"
        },
        {
          "name": "Obicetrapib Placebo",
          "type": "OTHER"
        },
        {
          "name": "Ezetimibe Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 407,
      "start_date": "2024-03-01",
      "completion_date": "2024-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 45,
      "location_summary": "Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06005597"
    },
    {
      "nct_id": "NCT04770389",
      "title": "Randomized Study of Obicetrapib in Combination With Ezetimibe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib 5mg",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 112,
      "start_date": "2021-02-23",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 3,
      "location_summary": "Lincoln, California • Evanston, Illinois • Houston, Texas",
      "locations": [
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770389"
    },
    {
      "nct_id": "NCT01763827",
      "title": "Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 615,
      "start_date": "2013-01-21",
      "completion_date": "2013-10-29",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763827"
    },
    {
      "nct_id": "NCT00120289",
      "title": "Niacin Plus Statin to Prevent Vascular Events",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Heart Diseases",
        "Cerebrovascular Accident",
        "Coronary Disease",
        "Atherosclerosis",
        "Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Extended release niacin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axio Research. LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 3414,
      "start_date": "2005-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-06",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 68,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Pheonix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00120289"
    },
    {
      "nct_id": "NCT00461968",
      "title": "Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cholesterol, LDL"
      ],
      "interventions": [
        {
          "name": "Ezetimibe and Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "20 Years to 70 Years · Male only"
      },
      "enrollment_count": 240,
      "start_date": "2005-02",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2007-04-18",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00461968"
    },
    {
      "nct_id": "NCT00405067",
      "title": "The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "BMS-201038 (AEGR-733)",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-05",
      "completion_date": "2007-01",
      "has_results": true,
      "last_update_posted_date": "2014-03-04",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00405067"
    },
    {
      "nct_id": "NCT07219602",
      "title": "A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lipidemia",
        "Type 2 Diabetes (T2DM)",
        "Metabolic Syndrome (MetS)"
      ],
      "interventions": [
        {
          "name": "obicetrapib 10 mg + ezetimibe 10 mg FDC daily",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2025-12-11",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 32,
      "location_summary": "Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more",
      "locations": [
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219602"
    },
    {
      "nct_id": "NCT05763875",
      "title": "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 350,
      "start_date": "2023-03-15",
      "completion_date": "2024-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05763875"
    },
    {
      "nct_id": "NCT05266586",
      "title": "Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 10mg",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib placebo",
          "type": "OTHER"
        },
        {
          "name": "Ezetimibe placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 119,
      "start_date": "2022-03-09",
      "completion_date": "2022-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-09-10T20:01:33.319Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Northridge, California • Ocala, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05266586"
    }
  ]
}